New Obesity Drugs Previewed

This is a news story, published by Gizmodo, that relates primarily to McGill University news.

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

Gizmodo news

For more news from Gizmodo, you can click here:

more news from Gizmodo

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

best obesity treatments

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest other related obesity treatments news, Ozempic news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

obesity treatment

Gizmodo

•

Ozempic is just the beginning of a new era of GLP-1 drugs

Summary

Nutrition label

72% Informative

Researchers at McGill University reviewed clinical trials of GLP-1 drugs like Ozempic and Wegovy .

They reaffirmed the safety and effectiveness of today ’s drugs.

But they highlighted the potential superiority of newer compounds such as retatrutide, which has helped people lose more than 20% of their original body weight in trials.

Whether that actually happens, we’ll have to see. But it’s almost certain that there will be plenty of drugs coming for semaglutide and tirzepatide’s current crown as the best obesity treatments around..

VR Score

Informative language

Neutral language

Article tone

informal

Language

English

Language complexity

Offensive language

not offensive

Hate speech

not hateful